2024 Fiscal Year Research-status Report
Elucidation of salivary gland uptake mechanisms and therapy application of 211At-PSMA ligand
| Project/Area Number |
23K27555
|
|---|
| Allocation Type | Multi-year Fund |
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
織内 昇 福島県立医科大学, 公私立大学の部局等, 教授 (40292586)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
関亦 明子 福島県立医科大学, 看護学部, 教授 (50321823)
小島 祥敬 福島県立医科大学, 医学部, 教授 (60305539)
右近 直之 福島県立医科大学, 公私立大学の部局等, 講師 (70792985)
趙 松吉 福島県立医科大学, 公私立大学の部局等, 教授 (80374239)
|
|---|
| Project Period (FY) |
2024-04-01 – 2026-03-31
|
| Keywords | aargeted α therapy / 211At-PSMA / radiation sialadenitis / salivary gland / prostate cancer / xerostomia / radionuclide therapy |
|---|
| Outline of Annual Research Achievements |
The goal of this study was to elucidate the mechanism of salivary gland uptake of 211At-labeled compounds, and to develop a treatment for xerostomia caused by salivary gland disorders.
By evaluating the specific uptake of the 211At-PSMA ligand into the salivary glands of normal mice, we clarify the molecular mechanism of uptake in relation to receptors such as the involvement of SNARE proteins, and obtain knowledge that leads to the treatment of salivary gland disorders, including xerostomia.
We quantitatively evaluated the uptake of 211At-PSMA ligand into the salivary glands and other organs of normal mice and clarified the biodistribution of 211At-PSMA ligand. The molecular mechanism of 211At-PSMA ligand uptake will lead to the treatment of salivary gland disorders.
|
| Current Status of Research Progress |
Current Status of Research Progress
3: Progress in research has been slightly delayed.
Reason
We quantitatively evaluated the uptake of 211At-PSMA ligand into the salivary glands of normal mice and intended to clarify the molecular mechanism of 211At-PSMA ligand uptake in relation to receptors such as the involvement of SNARE proteins and obtain knowledge that will lead to the treatment of salivary gland disorders.
The 211At-PSMA ligand is administered to normal mice, and the removed salivary glands as well as major organs are analyzed to quantitate the absorbed dose of the salivary glands and other organs. The relationship between the absorbed dose estimated from the accumulation of 211At-PSMA ligands and the amount of salivation was not clarified.
|
| Strategy for Future Research Activity |
We are planning studies to clarify the mechanism by which 211At-PSMA ligands accumulate in the salivary glands by elucidating a molecule involved in the transport and receptor binding of 211At-PSMA ligands by inhibiting uptake by knockdown of the molecules in the salivary glands, and to develop a preventive method for radiation sialadenitis.
|
| Causes of Carryover |
This year, the experiment was carried out according to the plan, but it took time to create a model animal, a knockout mouse, and the experiment could not be carried out as planned. The creation of model animals will be completed in the first quarter of the next fiscal year, and the experiments scheduled for this fiscal year will be completed steadily. The amount used for the next fiscal year, which is carried over from this year, will be used for the experiment. After that, from the second quarter, the experiments planned for the next fiscal year will be carried out as scheduled.
|
-
-
-
-
[Presentation] Evaluation of the potential of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CD82 monoclonal antibody in a murine xenograft model2024
Author(s)
Songji Zhao, Noboru Oriuchi, Taro Tachibana, Ken-ichi Nishijima, Chiaki Hata, Naoyuki Ukon, Saki Shimoyama, Cai-Xia Wang, Taiki Joho, Akira Sugiyama, Kohshin Washiyama, Kazuhiro Takahashi, Takayuki Ikezoe
Organizer
Society of Nuclear Medicine and Molecular Imaging 2024
Int'l Joint Research
